MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Radius Health Company Profile (NASDAQ:RDUS)

Consensus Ratings for Radius Health (NASDAQ:RDUS) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $68.88 (86.25% upside)

Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
DateFirmActionRatingPrice TargetActions
5/31/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2016HC WainwrightInitiated CoverageBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Cantor FitzgeraldReiterated RatingBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageNeutral$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Jefferies GroupDowngradeBuy -> Hold$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016Bank of AmericaReiterated RatingBuy$89.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Deutsche BankInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015Maxim GroupDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Radius Health (NASDAQ:RDUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Radius Health (NASDAQ:RDUS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.80)($0.79)($0.80)
Q2 20161($0.99)($0.99)($0.99)
Q3 20161($1.05)($1.05)($1.05)
Q4 20161($1.01)($1.01)($1.01)
(Data provided by Zacks Investment Research)
Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Radius Health (NASDAQ:RDUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Radius Health (NASDAQ:RDUS)
DateHeadline
06/29/16 03:01 PMRADIUS HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/28/16 05:59 PMTop Stock Pick for Quarter: Radius Health, Inc. (NASDAQ:RDUS) - Engelwood Daily
06/28/16 05:59 PMRadius Health, Inc. (NASDAQ:RDUS) Company Rating and Target Watch - Telanagana Press
06/27/16 10:16 AMStock Tracing Lower on the Week Radius Health, Inc. (NASDAQ:RDUS) - Engelwood Daily
06/27/16 10:16 AMShare Update and Earnings Review for Radius Health, Inc. (NASDAQ:RDUS) - Press Telegraph
06/27/16 10:16 AMNext Weeks Broker Price Targets For Radius Health, Inc. (RDUS) - Fiscal Standard
06/26/16 05:08 PMStrong Sell Calls Recommendations For Radius Health, Inc. (NASDAQ:RDUS) At 0 - Investor Newswire
06/23/16 06:43 PMEquity Research and Technical Review on Radius Health, Inc. (NASDAQ:RDUS) - Press Telegraph
06/22/16 06:01 PMBig Earnings Movers: Radius Health, Inc. (RDUS) - iStreetWire
06/22/16 06:01 PMRadius Health, Inc. (NasdaqGM:RDUS) Stock Momentum at Critical Inflection Point - CML News
06/21/16 07:45 PMRadius Health opens Philadelphia facility with plans to hire 100-plus -
06/21/16 05:36 PMBoston-area biopharm firm to add 100 jobs in Philaelphia suburbs
06/20/16 07:38 AMStrong Buy Calls Count For Radius Health, Inc. (NASDAQ:RDUS) At 5 - Investor Newswire
06/20/16 07:38 AMThis Weeks Broker Views For Radius Health, Inc. (RDUS) - Fiscal Standard
06/08/16 09:04 AMRADIUS HEALTH INC. (NASDAQ:RDUS) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:46 AMConns Inc. (NASDAQ:CONN) Declined -1.39%: Radius Health, Inc. (NASDAQ:RDUS), JinkoSolar Holding Co., Ltd ... - KC Register
06/05/16 08:47 AMRadius Health's (RDUS) Buy Rating Reaffirmed at Canaccord Genuity - Let Me Know About This
06/03/16 06:42 PMWellCare Health Plans, Inc. (NYSE:WCG) Went Up 2.58%: Radius Health (NASDAQ:RDUS), Glu Mobile (NASDAQ ... - KC Register
06/03/16 08:58 AMShare Rating Focus on Radius Health, Inc. (NASDAQ:RDUS) - HNN - Share Rating Focus on Radius Health, Inc. (NASDAQ:RDUS)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1.57 on shares of Radius Health, Inc. (NASDAQ:RDUS). Covering analysts will ...
06/03/16 08:58 AMBuy, Sell Or Hold Rating For Radius Health, Inc. (RDUS)? - Share Trading News - Buy, Sell Or Hold Rating For Radius Health, Inc. (RDUS)?Share Trading News05/06/2016 – Cowen began new coverage on Radius Health, Inc. giving the company a “outperform” rating. 03/31/2016 – Radius Health, Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 70 price target on the stock.FDA accepts Radius Health's abaloparatide NDASeeking Alphaall 2 news articles »
06/02/16 09:06 AMTarget Price and Stock Performance Rundown for Radius Health, Inc. (NASDAQ:RDUS) - HNN - Target Price and Stock Performance Rundown for Radius Health, Inc. (NASDAQ:RDUS)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Radius Health, Inc. (NASDAQ:RDUS) ...and more »
06/02/16 09:06 AMFDA accepts Radius Health's abaloparatide NDA - Seeking Alpha - FDA accepts Radius Health's abaloparatide NDASeeking AlphaThe FDA accepts for review Radius Health's (NASDAQ:RDUS) New Drug Application (NDA) seeking approval of abaloparatide-SC for the treatment of osteoporosis in postmenopausal women. No action date (PDUFA) is given. Abaloparatide is a synthetic ...and more »
06/02/16 05:03 AMRADIUS HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
06/01/16 06:39 PMRadius Health (NASDAQ:RDUS) NDA for abaloparatide-SC accepted for filing by FDA: Amarin (NASDAQ:AMRN ... - KC Register - Radius Health (NASDAQ:RDUS) NDA for abaloparatide-SC accepted for filing by FDA: Amarin (NASDAQ:AMRN ...KC RegisterRadius Health, Inc. (NASDAQ:RDUS) announced that its New Drug Application (NDA) for abaloparatide–SC has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the ...and more »
06/01/16 03:58 PMRadius Health, Inc. :RDUS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 11:35 AMRadius Health to Present at the Goldman Sachs Thirty-Seventh Annual 2016 Healthcare Conference - [at noodls] - WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone ...
06/01/16 08:59 AMBMRN Pulls The Plug On DMD Drug, LXRX To Face FDA In Nov, TEVA Snubbed - LXRX closed Tuesday's trading at $14.21, up 3.87%. Radius Health Inc.'s (RDUS) New Drug Application for Abaloparatide-SC, an investigational treatment for postmenopausal women with osteoporosis, has been accepted for filing by the FDA. The FDA decision can ...
06/01/16 08:59 AMRadius Health (RDUS) Announces FDA Acceptance of NDA Filing for Abaloparatide-SC - Join here. Radius Health, Inc. (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application ...
05/31/16 06:23 PMRadius Health (RDUS) Announces FDA Acceptance of NDA Filing for Abaloparatide-SC - StreetInsider.com - Radius Health (RDUS) Announces FDA Acceptance of NDA Filing for Abaloparatide-SCStreetInsider.comRadius Health, Inc. (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA) ...Radius Reveals FDA Acceptance For Filing Of NDA For Abaloparatide-SC For Treatment Of Postmenopausal Women ...Benzingaall 2 news articles »
05/31/16 02:05 PMRadius Reveals FDA Acceptance For Filing Of NDA For Abaloparatide-SC For Treatment Of Postmenopausal Women With Osteoporosis -
05/31/16 01:23 PMRadius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis - [at noodls] - WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, ...
05/31/16 10:19 AMHC Wainwright Initiates Coverage on Radius Health Inc to Buy - Trade Calls - HC Wainwright Initiates Coverage on Radius Health Inc to BuyTrade CallsHC Wainwright Initiates Coverage on Radius Health Inc(NASDAQ:RDUS). The shares have been rated Buy. The rating by HC Wainwright was issued on May 23, 2016. In a different note, On May 6, 2016, Cowen & Company said it Assumes its rating on ...Radius Health, Inc. (RDUS) Broker Price Targets For The Coming WeekShare Trading NewsRadius Health, Inc. (NASDAQ:RDUS) One-Year Price Target At $59.14Vanguard TribuneRadius Health Incorporated (NASDAQ:RDUS) Sellers Increased By 1.98% Their ShortsFranklin Independentall 6 news articles »
05/27/16 03:19 PMRADIUS HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of -
05/27/16 11:45 AMRadius Health Inc Has Another Very Weak Trading Session - Wall Street Hints and News - Radius Health Inc Has Another Very Weak Trading SessionWall Street Hints and NewsThe stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! The stock decreased 3.58% or $1.25 during the last trading session, hitting $33.65. About 648,638 shares traded hands or 1.10% up from the average. Radius Health Inc ...
05/23/16 01:02 PMH.C. Wainwright Initiates Radius Health At Buy, $55 Target - H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States.
05/23/16 06:08 AMCoverage initiated on Radius Health by H.C. Wainwright -
05/21/16 12:45 AMAnalyst Rating Check on Radius Health, Inc. (NASDAQ:RDUS) - Wall Street Hints and News - Analyst Rating Check on Radius Health, Inc. (NASDAQ:RDUS)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1.67 on shares of Radius Health, Inc. (NASDAQ:RDUS). Analysts that cover the company ...and more »
05/21/16 12:45 AMRadius Health, Inc. (NASDAQ:RDUS) Hovering Around $32.04 - Investor Newswire - Radius Health, Inc. (NASDAQ:RDUS) Hovering Around $32.04Investor NewswireOn performing technical analysis of Radius Health, Inc. (NASDAQ:RDUS) stock, it is noted that the stock is $-1.68 points away -4.88% from its fifty-day MA of $34.49. It is $-10.28 or -23.85% away $43.09, the 200-day MA (Moving Average) of stock. Also ...
05/19/16 10:43 AMShare Performance and Target Price Review for Radius Health, Inc. (NASDAQ:RDUS) - Wall Street Hints and News - Share Performance and Target Price Review for Radius Health, Inc. (NASDAQ:RDUS)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Radius Health, Inc. (NASDAQ:RDUS) ...and more »
05/19/16 10:43 AMSnapshot of Recent Traded Stocks: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) , Radius Health, Inc. (NASDAQ:RDUS) - Street Updates - Snapshot of Recent Traded Stocks: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) , Radius Health, Inc. (NASDAQ:RDUS)Street UpdatesRadius Health, Inc. (NASDAQ:RDUS) moved in red zone with decline of -0.17 points or -0.51% to $32.90. The company has a market worth of $1.42B.Total 523.28 thousand shares were exchanged in last trading session as opposed to average volume of ...and more »
05/17/16 11:44 AMRevenue Update on Radius Health Inc(NASDAQ:RDUS) - Trade Calls - Revenue Update on Radius Health Inc(NASDAQ:RDUS)Trade CallsRadius Health Inc(NASDAQ:RDUS) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Earnings per share were $-0.94. Analysts had estimated an EPS of $-0.74. In a different note, Goldman ...After Last Week What Do Analysts Think Of Radius Health, Inc. (RDUS)Share Trading Newsall 3 news articles »
05/16/16 01:21 PMNext Weeks Broker Price Targets For Radius Health, Inc. (RDUS) - Share Trading News - Next Weeks Broker Price Targets For Radius Health, Inc. (RDUS)Share Trading NewsRadius Health, Inc. has a 50 day moving average of 34.46 and a 200 day moving average of 44.03. The stock's market capitalization is 1.31B, it has a 52-week low of 24.75 and a 52-week high of 84.64. The share price of the company (RDUS) was up +0.66%, ...
05/14/16 07:08 PMRadius Health : Announces New Employment Inducement Grants - (GlobeNewswire) - Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on May 8, 2016, the compensation ...
05/13/16 05:18 AMStock Earnings Analysis: Radius Health Inc (NASDAQ:RDUS) - News Oracle - News OracleStock Earnings Analysis: Radius Health Inc (NASDAQ:RDUS)News OracleLast Trade: The Company fell -4.09% and finished at $32.16. The daily volume was measured at 633,900.00 shares. The 52-week high of the share price is $84.64 and the 52-week low is $24.75. The company has a market cap of $1.39 Billion. Its latest ...and more »
05/12/16 12:04 PMRADIUS HEALTH, INC. Financials -
05/10/16 09:56 PMEarnings Trend per share for Investors: Radius Health Inc (NASDAQ:RDUS) - News Oracle - Earnings Trend per share for Investors: Radius Health Inc (NASDAQ:RDUS)News OracleLast Trade: The Company rose 7.60% and finished at $33.28. The daily volume was measured at 832,500.00 shares. The 52-week high of the share price is $84.64 and the 52-week low is $24.75. The company has a market cap of $1.45 Billion. Its latest ...and more »
05/07/16 01:26 AMRadius Health (RDUS) Reports Wider-than-Expected Q1 Loss - Nasdaq - Web Breaking NewsRadius Health (RDUS) Reports Wider-than-Expected Q1 LossNasdaqRadius Health, Inc . RDUS posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents, primarily due to an increase in research and development ...Radius Health, Inc. (RDUS) Latest Broker ViewsRisers & FallersRadius Health, Inc. (NASDAQ:RDUS) 50-day MA At $34.68Investor NewswireHow Will Radius Health (NASDAQ:RDUS) Stock React To Cowen New Rating Coverage?Franklin IndependentWeb Breaking News -B.O.D.Y Confidential -eMarketsDailyall 7 news articles »
05/06/16 02:54 PMRadius Health (RDUS) Reports Wider-than-Expected Q1 Loss -
05/06/16 12:00 PMEdited Transcript of RDUS earnings conference call or presentation 5-May-16 12:00pm GMT -
05/05/16 05:36 AM6:36 am Radius Health misses by $0.19 -
About Radius Health

Radius Health logoRadius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company's lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its abaloparatide-SC is under regulatory review in Europe. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis, and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, which is an orally bioavailable non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under investigation for potential applications in oncology and multiple conditions.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RDUS
  • CUSIP:
Key Metrics:
  • Previous Close: $36.98
  • 50 Day Moving Average: $35.19
  • 200 Day Moving Average: $37.31
  • P/E Ratio: N/A
  • P/E Growth: -3.21
  • Market Cap: $1.59B
  • Current Quarter EPS Consensus Estimate: $-3.71 EPS
Additional Links:
Radius Health (NASDAQ:RDUS) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha